Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bmab1800 versus Keytruda adjuvant monotherapy in resected melanoma
PACTR202605570676346Phase 1Not yet recruiting
- Sponsor
- Mylan
- Start
- Aug 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, randomised trial of pembrolizumab in melanoma (2 arms), sponsored by Mylan. Primary endpoint: Pharmacokinetic equivalence. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on PACTR202605570676346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605570676346.